Z
Ziphius Vaccines
Addresses urgent global public health needs by developing mRNA-based vaccines
About Ziphius Vaccines
Ziphius is a biotechnology startup that specializes in the development of lipid nanoparticle (LNP) libraries for the delivery of self-amplifying RNA (saRNA). In simpler terms, they create tiny particles that can carry genetic material into cells. This technology is particularly useful in the creation of vaccines and gene therapies. Their target market includes healthcare providers and research institutions seeking innovative solutions for infectious diseases and rare genetic disorders.
Read full description
The company's business model revolves around the development and optimization of their LNP-saRNA platform. They aim to improve the delivery of saRNA to specific organs and tissues, thereby reducing toxicity and enhancing the effectiveness of vaccines and gene therapies. Unlike conventional mRNA, saRNA can replicate itself, allowing for a larger amount of genetic material to be delivered at a lower dosage. This makes saRNA a more efficient and cost-effective solution.
Ziphius generates revenue by licensing its technology to healthcare providers and research institutions. They also aim to create partnerships with other biotech companies to further develop and commercialize their technology. The company's team is composed of experts in various fields, including biology, virology, chemistry, and pharmaceutical sciences. They recently appointed Johan Van Hoof, former head of Janssen Vaccines R&D, as Chief Scientific Advisor, signaling their commitment to advancing vaccine research and development.
At a glance
- Status
- Operational
- Founded
- 2019
- Headquarters
- Ghent, Belgium
- Employees
- 45
- Open positions
- None listed
- Dealroom signal
- 60.7/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Vaccines, Genetics and genomics, Biotech and Pharma, mRNA Medicines, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| CONVERTIBLE✓Equity / VC | May 2021 | $5.5M | — | Undisclosed | ↗ |
| SERIES A✓Equity / VC | May 2021 | $27M | $107M | Annie Vereecken · Christian Dumolin | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Ziphius Vaccines is 810 monthly website visits, up 55.8% over the last three months. Ziphius Vaccines's team declined 4.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Annie Vereecken
Christian Dumolin
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Ziphius Vaccines on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Ziphius Vaccines’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.